Treatment-Resistant Depression Market to Witness an Outstanding Growth by 2027
Posted by Aman Jaiswar on September 17th, 2019
Depression is feeling of sadness that interferes with functioning and/or a decreased interest or pleasure in activities. It has a number of side effects, such as change in hormonal levels and emotionally distressing events, and hereditary and side effects of drugs lead to depression. Antidepressants, electroconvulsive therapy, and psychotherapy may help to treat the patient suffering from depression.
Treatment-resistant depression is a disorder where the patient does not respond to antidepressants used to treat the condition. The effect of antidepressants is observed to be minimal or nil in case of treatment-resistant depression.
Expansion of the Treatment-Resistant Depression Market is anticipated to be driven by increase in demand for new therapies for treatment-resistant depression, promising products in pipeline, and approved drugs by the Food and Drug Administration (FDA).
NMDA receptor antagonists and combination drugs developed by Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services, Inc.) and Eli Lilly and Company, respectively, are available to treat drug-resistant depression. These medications are available in the form of nasal sprays and tablets.
To obtain all-inclusive information on forecast analysis of Global Treatment-Resistant Depression Market, Request a PDF Brochure Here
Prominent market players have entered into agreement for the development of new therapeutics in neurological disorders. In March 2019, Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services, Inc.) received the FDA approval for SPRAVATO (esketamine) CIII, a nasal spray used in combination with an oral antidepressant in adults with treatment-resistant depression. Evotec AG entered into a license agreement with Janssen Pharmaceuticals, Inc. regarding its NR2B subtype selective NMDA-antagonist portfolio indicated for depression disorders. As per the agreement, Janssen Pharmaceuticals, Inc. was granted worldwide license to a series of small molecule drug candidates, develop the compounds, and market the products.
In September 2019, Evotec AG and F. Hoffmann-La Roche Ltd entered into an agreement for Phase II clinical development of EVT 101 indicated for treatment-resistant depression
Major players operating in the global treatment-resistant depression market are Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services, Inc.) and Eli Lilly and Company.
Like it? Share it!
About the AuthorAman Jaiswar
Joined: May 14th, 2019
Articles Posted: 1,020
More by this author